¼¼°èÀÇ ³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀå
Brain Tumor Diagnosis and Treatment
»óǰÄÚµå : 1760847
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 173 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,121,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,364,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 20¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 4.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 20¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿ø¹ß¼º ³úÁ¾¾çÀº CAGR 4.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2Â÷¼º ³úÁ¾¾ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 1,050¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 4¾ï 1,050¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 7.7%·Î 2030³â±îÁö 4¾ï 5,510¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.7%¿Í 4.6%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.7%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀåÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀåÀº ¿µ»ó±â¼úÀÇ ¹ßÀü°ú Ç¥ÀûÄ¡·áÁ¦ÀÇ °³¹ß·Î ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ Ä¡·á¸¦ À§Çؼ­´Â Á¶±â Áø´ÜÀÌ ÇʼöÀûÀ̸ç, MRI, CT ½ºÄµ, PET ½ºÄµ µîÀÇ ±â¼ú Çõ½ÅÀ¸·Î °ËÃâ Á¤È®µµ°¡ Çâ»óµÇ°í Áø´Ü ½Ã°£ÀÌ ´ÜÃàµÇ°í ÀÖ½À´Ï´Ù. Ä¡·á´Â ¼ö¼úÀ̳ª ¹æ»ç¼±°ú °°Àº ÀüÅëÀûÀÎ ¹æ¹ý¿¡¼­ Ç¥Àû ¾à¹° Ä¡·á³ª ¸é¿ªÄ¡·á¿Í °°ÀÌ ÁÖº¯ °Ç°­ÇÑ Á¶Á÷ÀÇ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾ç ¼¼Æ÷¸¦ º¸´Ù Á¤È®ÇÏ°Ô °ø°ÝÇÏ´Â º¸´Ù Áøº¸µÈ Ä¡·á¹ýÀ¸·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

³úÁ¾¾ç Ä¡·áÀÇ ¹ßÀü¿¡¼­ ±â¼úÀº ¾î¶² ¿ªÇÒÀ» Çϰí Àִ°¡?

AI ±â¹Ý Áø´Ü µµ±¸, Á¤À§Àû ¹æ»ç¼± ¼ö¼ú, °³ÀÎ ¸ÂÃãÇü ÀÇ·á µîÀÇ Çõ½ÅÀ» ÅëÇØ ³úÁ¾¾ç Ä¡·áÀÇ ¹ßÀü¿¡ Çõ½ÅÀû ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, AI ¾Ë°í¸®ÁòÀº ±âÁ¸ ¹æ¹ýº¸´Ù ´õ ³ôÀº Á¤È®µµ·Î ÀÇ·á ¿µ»óÀ» ºÐ¼®ÇÏ¿© Á¾¾çÀÇ °ËÃâ ¹× Æ¯¼ºÈ­ Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °¨¸¶³ªÀÌÇÁ³ª »çÀ̹ö³ªÀÌÇÁ¿Í °°Àº Á¤À§Àû ¹æ»ç¼± ¼ö¼úÀº °Ç°­ÇÑ Á¶Á÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾çÀ» ¸ñÇ¥·Î ÇÏ´Â ºñħ½ÀÀûÀ̰í Á¤¹ÐÇÑ ¹æ»ç¼± Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµÀ» Æ÷ÇÔÇÑ °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀº ȯÀÚ °³°³ÀÎÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

½ÃÀå ¿ªÇÐ ¹× ȯÀÚÃþÀº ³úÁ¾¾ç Ä¡·á¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

½ÃÀå ¿ªÇÐ ¹× ȯÀÚÃþÀº ³úÁ¾¾ç Ä¡·á¸¦ Å©°Ô Á¿ìÇϰí ÀÖÀ¸¸ç, ȯÀÚ Áß½ÉÀÇ ¸ÂÃã Ä¡·á Á¢±Ù¹ý¿¡ Á¡Á¡ ´õ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ³úÁ¾¾ç ¹ßº´·ü Áõ°¡, ƯÈ÷ °í·ÉÈ­·Î ÀÎÇØ º¸´Ù È¿°úÀûÀÌ°í ´ú ħ½ÀÀûÀÎ Áø´Ü ¹× Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ú °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ½Å°æÁ¾¾çÇÐÀÌ ¹ßÀüÇÔ¿¡ µû¶ó Á¶±â Áø´Ü°ú ´ÙÇÐÁ¦Àû Ä¡·á °èȹÀÌ Àå·ÁµÇ°í ÀÖ½À´Ï´Ù. °í±Þ ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÇ Áö¿ªÀû °ÝÂ÷µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÁö¸¸, ºÏ¹Ì¿Í À¯·´Àº ÀÇ·á ÀÎÇÁ¶ó¿Í ¿¬±¸½Ã¼³ÀÌ Àß °®Ãß¾îÁ® ÀÖ¾î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

³úÁ¾¾ç Áø´Ü ¹× Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¿µ»ó ±â¼úÀÇ ¹ßÀü, Ç¥Àû Ä¡·á ¹× ¸é¿ª ¿ä¹ýÀÇ °³¹ß, Àü ¼¼°è ³úÁ¾¾ç ¹ß»ý·ü Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü¿¡ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº °¨ÁöÀ²°ú Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Ä¡·á ¿É¼Ç°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀåÀ» Çõ½ÅÀûÀÎ Á¢±Ù ¹æ½ÄÀ¸·Î À̲ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ ÁöÃâ Áõ°¡, ÀÎ½Ä °³¼±, ¾Ï ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀçÁ¤ Áö¿øµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¾¾ç À¯Çü(¿ø¹ß¼º ³úÁ¾¾ç, ¿¬¹ß¼º ³úÁ¾¾ç), Áø´Ü À¯Çü(CT ½ºÄµ, MRI, PET-CT ½ºÄµ, ¿äÃß ÃµÀÚ, ³úÆÄ, Á¶Á÷ »ùÇøµ, ±âŸ Áø´Ü À¯Çü), Ä¡·á À¯Çü(¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç¥ÀûÄ¡·á, È­Çпä¹ý, ¸é¿ªÄ¡·á, ±âŸ Ä¡·á À¯Çü)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 42°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Brain Tumor Diagnosis and Treatment Market to Reach US$2.0 Billion by 2030

The global market for Brain Tumor Diagnosis and Treatment estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Primary Brain Tumor, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Secondary Brain Tumor segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$410.5 Million While China is Forecast to Grow at 7.7% CAGR

The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$410.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$455.1 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Brain Tumor Diagnosis and Treatment Market - Key Trends & Drivers Summarized

How Is the Brain Tumor Diagnosis and Treatment Market Evolving?

The brain tumor diagnosis and treatment market is evolving rapidly due to advancements in imaging technologies and the development of targeted therapies. Early diagnosis is critical for effective treatment, and innovations such as MRI, CT scans, and PET scans are enhancing detection accuracy and reducing diagnostic times. In terms of treatment, there is a shift from traditional methods like surgery and radiation to more advanced options such as targeted drug therapy and immunotherapy, which offer better precision in targeting tumor cells while minimizing damage to surrounding healthy tissues.

What Role Does Technology Play in Advancing Brain Tumor Treatment?

Technology is playing a transformative role in advancing brain tumor treatment through innovations like AI-powered diagnostic tools, stereotactic radiosurgery, and personalized medicine. AI algorithms are improving the accuracy of tumor detection and characterization by analyzing medical imaging with greater precision than conventional methods. Stereotactic radiosurgery, such as Gamma Knife and CyberKnife, allows for non-invasive, high-precision radiation treatment that targets tumors with minimal impact on healthy tissues. Personalized treatment approaches, including genetic profiling, are enabling the development of targeted therapies tailored to individual patient profiles.

How Are Market Dynamics and Patient Demographics Shaping Brain Tumor Care?

Market dynamics and patient demographics are significantly shaping brain tumor care, with an increasing emphasis on patient-centered and personalized treatment approaches. The rising incidence of brain tumors, particularly among aging populations, is driving demand for more effective and less invasive diagnostic and therapeutic options. Additionally, the growing awareness of brain health and advancements in neuro-oncology are encouraging early diagnosis and multidisciplinary treatment plans. Regional disparities in access to advanced care are also influencing market growth, with North America and Europe leading due to well-established healthcare infrastructure and research facilities.

What Factors Are Driving the Growth in the Brain Tumor Diagnosis and Treatment Market?

The growth in the brain tumor diagnosis and treatment market is driven by several factors, including advancements in imaging technologies, the development of targeted and immunotherapies, and the increasing incidence of brain tumors globally. The integration of AI and machine learning in diagnostics is improving detection rates and accuracy. The rising demand for non-invasive treatment options and personalized medicine is pushing the market towards innovative approaches. Furthermore, increasing healthcare expenditure, awareness, and government funding for cancer research are also contributing to the market's expansion.

SCOPE OF STUDY:

The report analyzes the Brain Tumor Diagnosis and Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Tumor Type (Primary Brain Tumor, Secondary Brain Tumor); Diagnosis Type (CT Scan, MRI, PET-CT Scan, Lumbar Puncture, EEG, Tissue Sampling, Other Diagnosis Types); Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy, Other Treatment Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â